Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839289 · ClinicalTrials.gov registry record · NA
Hearing Aid Signal Processing Comparative Study
A NA study, sponsored by Sonova.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT04839289: Completed NA study, sponsored by Sonova.
NCT04839289 is a NA study that has completed, run by Sonova. The registered enrollment target is 27 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04839289, a NA study, has completed, sponsored by Sonova.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
Participants will be fit with each of two hearing instruments in an ABA cross-over design. The study will consist of a total of three approximately 10-day home trials with the devices. Participants will be asked to provide qualitative feedback to investigators regarding the performance of and their preference for each hearing instrument.
Primary Outcome
Qualitative feedback questionnaire to gather feedback on particular areas of focus. Subjects will rate hearing performance and sound quality on a Likert scale with lowest number equivalent to worst performance or worst sound quality (1) and higher number equivalent to best performance or best sound quality (10).
Interventions
- DEVICE Receiver-in-canal hearing instrument; Manufacturer A
- DEVICE Receiver-in-canal hearing instrument; Manufacturer B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2021-08-31 |
| Phase | NA |
What the finished NCT04839289 record still lists
NCT04839289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Receiver-in-canal hearing instrument; Manufacturer A is the first listed.
NCT04839289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04839289 about?
NCT04839289 is a clinical study titled "Hearing Aid Signal Processing Comparative Study". Participants will be fit with each of two hearing instruments in an ABA cross-over design. The study will consist of a total of three approximately 10-day home trials with the devices. Participants will be asked to provide qualitative feedback to investigators regarding the performance of and their ...
What is the current status of trial NCT04839289?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2021-07-01. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT04839289?
The interventions under investigation include: Receiver-in-canal hearing instrument; Manufacturer A (DEVICE), Receiver-in-canal hearing instrument; Manufacturer B (DEVICE).
Who is sponsoring clinical trial NCT04839289?
This trial is sponsored by Sonova, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04839289's enrollment target sits among peer trials
27 1708th of 2000 higher than 291 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI